Serum Anti-PCOLCE as Novel Diagnostic Biomarker in Rheumatoid Arthritis With Emphasis on Seronegative Patients.

Launched by ASSIUT UNIVERSITY · Aug 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help diagnose rheumatoid arthritis (RA), a condition that causes joint pain, swelling, and damage. Right now, doctors use certain blood tests to identify RA, but these tests don’t work for about 30% of patients, making it hard to confirm their diagnosis. This study will test whether a new blood marker called anti-PCOLCE can help detect RA, especially in those patients whose current tests come back negative.

Adults diagnosed with RA who meet specific medical criteria may be eligible to join the study. Participants will have their health checked through physical exams, questionnaires about their symptoms and daily activities, and blood tests to measure this new marker. The goal is to see if anti-PCOLCE can be a reliable tool to improve early and accurate diagnosis of RA, which can help patients get the right treatment sooner and prevent joint damage. The study is not yet recruiting, so if you or a loved one has RA and are interested, it’s good to stay informed for when enrollment begins.

Gender

ALL

Eligibility criteria

• • Adults (≥18 years old).
• Patients clinically diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria:
• • -
• • Patients with other autoimmune or connective tissue diseases (e.g., SLE, SS). Patients with chronic infections or malignancies. Patients less than 18 years old.
• • -